Stryker Corporation (SYK) Position Maintained by Busey Trust CO

Busey Trust CO maintained its stake in Stryker Corporation (NYSE:SYK) during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 5,199 shares of the medical technology company’s stock at the end of the fourth quarter. Busey Trust CO’s holdings in Stryker Corporation were worth $623,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Capital Research Global Investors boosted its stake in Stryker Corporation by 1.7% in the third quarter. Capital Research Global Investors now owns 33,537,131 shares of the medical technology company’s stock valued at $3,904,057,000 after buying an additional 556,349 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Stryker Corporation by 6.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 17,503,094 shares of the medical technology company’s stock valued at $2,037,535,000 after buying an additional 1,022,233 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Stryker Corporation by 2.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 11,990,001 shares of the medical technology company’s stock valued at $1,436,761,000 after buying an additional 328,431 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its stake in Stryker Corporation by 1.1% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 8,620,753 shares of the medical technology company’s stock valued at $1,003,542,000 after buying an additional 95,303 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its stake in Stryker Corporation by 2.4% in the third quarter. BlackRock Fund Advisors now owns 6,428,304 shares of the medical technology company’s stock valued at $748,319,000 after buying an additional 147,788 shares in the last quarter. 75.29% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Shares of Stryker Corporation (NYSE:SYK) opened at 124.33 on Tuesday. The stock’s 50 day moving average is $121.79 and its 200 day moving average is $116.47. Stryker Corporation has a 52-week low of $95.79 and a 52-week high of $127.23. The company has a market cap of $46.56 billion, a PE ratio of 28.58 and a beta of 0.80.

Stryker Corporation (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 24th. The medical technology company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.76 by $0.02. The business earned $3.20 billion during the quarter, compared to analysts’ expectations of $3.15 billion. Stryker Corporation had a return on equity of 23.86% and a net margin of 14.54%. The business’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.56 EPS. Equities analysts forecast that Stryker Corporation will post $6.41 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 28th. Stockholders of record on Friday, March 31st will be paid a $0.425 dividend. This represents a $1.70 annualized dividend and a dividend yield of 1.37%. The ex-dividend date of this dividend is Wednesday, March 29th. Stryker Corporation’s payout ratio is presently 39.08%.

“Stryker Corporation (SYK) Position Maintained by Busey Trust CO” was first published by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another publication, it was illegally copied and reposted in violation of US & international copyright legislation. The correct version of this piece can be viewed at http://sleekmoney.com/stryker-corporation-syk-position-maintained-by-busey-trust-co/1659984.html.

SYK has been the subject of several research reports. Guggenheim set a $137.00 price target on shares of Stryker Corporation and gave the stock a “buy” rating in a research note on Wednesday, January 25th. Zacks Investment Research lowered shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research note on Monday, November 14th. Canaccord Genuity raised their price objective on shares of Stryker Corporation from $127.00 to $137.00 and gave the company a “buy” rating in a research note on Wednesday, January 25th. Needham & Company LLC restated a “sell” rating on shares of Stryker Corporation in a research note on Wednesday, January 25th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $134.50 price objective on shares of Stryker Corporation in a research note on Saturday, January 28th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $125.75.

In other news, Director Louise Francesconi sold 3,716 shares of Stryker Corporation stock in a transaction dated Monday, January 30th. The stock was sold at an average price of $122.34, for a total value of $454,615.44. Following the completion of the transaction, the director now owns 20,242 shares in the company, valued at approximately $2,476,406.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 6,000 shares of Stryker Corporation stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $112.01, for a total value of $672,060.00. Following the completion of the transaction, the director now owns 193,142 shares of the company’s stock, valued at approximately $21,633,835.42. The disclosure for this sale can be found here. Insiders sold a total of 194,570 shares of company stock valued at $22,485,637 in the last quarter. Company insiders own 7.80% of the company’s stock.

About Stryker Corporation

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/stryker-corporation-syk-position-maintained-by-busey-trust-co/1659984.html

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *